2472-78-8

Upstream product

• 33347-88-5 2-methyl-6-(4-methoxyphenyl)-4,5-dihydro-3(2H)-pyridazinone 
• 15118-67-9 ethyl 3-(4-methoxybenzoyl)-propionate 
• 1017-06-7 6-(4-Methoxyphenyl)-4,5-dihydro-2H-pyridazin-3-one 
• 3153-44-4 4-(4-methoxy-phenyl)-4-oxo-butyric acid 

Downstream Products

• 127019-66-3 3a,7a-dihydro-3-(2,4,6-trimethylphenyl)-4-oxo-5-methyl-7-(4-methoxyphenyl)isoxazolo<4,5-d>pyridazine 
• 127019-67-4 3-(2,6-Dichloro-phenyl)-7-(4-methoxy-phenyl)-5-methyl-5,7a-dihydro-3aH-isoxazolo[4,5-d]pyridazin-4-one 
• 1005402-20-9 6-(4-hydroxyphenyl)-2-methyl-2H-pyridazin-3-one 
• 1005402-21-0 6-[4-(3-chloropropoxy)phenyl]-2-methyl-2H-pyridazin-3-one 
• 1005401-46-6 2-methyl-6-{4-[3-((R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one hydrochloride 
• 1333420-46-4 C₁₅H₁₈N₂O₃ 
• 1333420-51-1 C₁₅H₁₈N₂O₃ 

Relevant academic research and scientific papers

4-Phenoxypiperidine pyridazin-3-one histamine H3 receptor inverse agonists demonstrating potent and robust wake promoting activity

Structure-activity relationships for a series of phenoxypiperidine pyridazin-3-one H3R antagonists/ inverse agonists are disclosed. The search for compounds with improved hERG and DAT selectivity without the formation of in vivo active metaboli

Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl) propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): A potent, selective histamine H3 receptor inverse agonist

Optimization of a novel series of pyridazin-3-one histamine H3 receptor (H3R) antagonists/inverse agonists identified 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (8a, CEP-26401; irdabisant) as a lead candid

Iodine-mediated facile dehydrogenation of dihydropyridazin-3(2H)one

A new protocol for the dehydrogenation of dihydropyridazin-3(2H)-one has been carried out by catalytic amount of iodine in dimethyl sulphoxide in good yield with easy workup.

Amine-constrained pyridazinone histamine H3 receptor antagonists

Pyridazinone 1 was recently reported as a potent H3R antagonist with good drug-like properties and in vivo activity. A series of constrained amine analogs of 1 was synthesized to identify compounds with improved pharmacokinetic profiles. From these efforts, a new class of (S)-2-pyrrolidin-1-ylmethyl-1-pyrrolidinyl amides was identified.

Identification of pyridazin-3-one derivatives as potent, selective histamine H3 receptor inverse agonists with robust wake activity

H3R structure-activity relationships on a novel class of pyridazin-3-one H3R antagonists/inverse agonists are disclosed. Modifications of the pyridazinone core, central phenyl ring and linker led to the identification of molecules wi

Pyridizinone derivatives

The present invention provides compounds of formula (I*): their use as H3 inhibitors, processes for their preparation, and pharmaceutical compositions thereof.